Crossmark

Novel FABP4+C1q+ macrophages enhance antitumor immunity and associated with response to neoadjuvant pembrolizumab and chemotherapy in NSCLC via AMPK/JAK/STAT axis

Crossref DOI link: https://doi.org/10.1038/s41419-024-07074-x

Published Online: 2024-10-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Dong

Wang, Min

Liu, Gen

Li, Xin

Yu, Wenwen

Hui, Zhenzhen

Ren, Xiubao https://orcid.org/0000-0003-4137-2049
Sun, Qian https://orcid.org/0000-0002-4878-3599
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82373283, 82372779, U20A20375)
License Information

Text and Data Mining valid from 2024-10-01

Version of Record valid from 2024-10-01
More Information

Article History

Received: 4 March 2024

Revised: 7 September 2024

Accepted: 12 September 2024

First Online: 1 October 2024

Competing interests

: The authors declare no competing interests.

: This study was approved by the Ethical Committee of TMUCIH, and all patients were informed and signed the consent form (NO.: bc2020060).

Document is current

Any future updates will be listed below